Lori M Minasian
Affiliation: National Institutes of Health
- Prevention and early detection clinical trials: opportunities for primary care providers and their patientsLeslie G Ford
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
CA Cancer J Clin 53:82-101. 2003....
- Health-related quality of life and symptom management research sponsored by the National Cancer InstituteLori M Minasian
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7340, USA
J Clin Oncol 25:5128-32. 2007..The scope of NCI's research in symptom management and HRQOL is described with attention to its evolution over time and the next steps, through the Clinical Trials Working Group Recommendations...
- Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experienceDavid R Buchanan
National Cancer Institute, 6130 Executive Plaza, Rm 2149, Bethesda, MD 20892 7317, USA
J Clin Oncol 23:6682-9. 2005..To identify major research-design issues in proposals submitted by investigators in the Community Clinical Oncology Program (CCOP) for clinical trials of complementary and alternative medicine (CAM) for cancer-symptom management...
- Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translationAndrew N Freedman
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7393, USA
J Natl Cancer Inst 102:1698-705. 2010....
- A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)Barbara K Dunn
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Nutr Cancer 62:896-918. 2010..07, P = 0.16) were observed. SELECT data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men...
- Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology ProgramLori M Minasian
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
Cancer 116:4440-9. 2010..By describing its keys to success, this article provides practical guidance to cancer-focused, provider-based research networks as well as those in other disciplines...
- Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology ProgramDavid R Buchanan
Division of Cancer Prevention, National Cancer Institute NIH, 6130 Executive Blvd, Room EPN 2149, Bethesda, MD 20892 7317, USA
J Clin Oncol 23:591-8. 2005..To examine how quality of life (QOL) is prospectively conceptualized, defined, and measured in the symptom management clinical trials supported by the National Cancer Institute Community Clinical Oncology Program (CCOP)...
- Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experienceWorta McCaskill-Stevens
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 23:5247-54. 2005..This article examines temporal trends in MBCCOP accruals to cancer prevention and control (CP/C) and cancer treatment trials and the racial distribution of study participants, along with the major factors affecting minority enrollment...
- Patient-reported outcomes assessment in cancer trials: taking stock, moving forwardJoseph Lipscomb
Emory University, Atlanta, GA 30322, USA
J Clin Oncol 25:5133-40. 2007....
- Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman
The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Natl Cancer Inst 97:94-102. 2005....
- Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Elise D Cook
Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, Houston 77230 1439, USA
Clin Trials 2:436-42. 2005..The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer...